TNXP — Tonix Pharmaceuticals Holding Balance Sheet
0.000.00%
- $163.22m
- $37.89m
- $10.09m
- 27
- 28
- 25
- 14
Annual balance sheet for Tonix Pharmaceuticals Holding, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 77.1 | 179 | 120 | 24.9 | 98.8 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | — | 4.82 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 88 | 189 | 131 | 47.8 | 119 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 9.83 | 51.5 | 94.5 | 94.9 | 42.8 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 98.2 | 241 | 226 | 154 | 163 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.82 | 21.7 | 18.2 | 18.9 | 18.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 10.5 | 22.2 | 18.5 | 48.9 | 23.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 87.6 | 219 | 207 | 106 | 140 |
| Total Liabilities & Shareholders' Equity | 98.2 | 241 | 226 | 154 | 163 |
| Total Common Shares Outstanding |